DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT07176663

Tirzepatide

Not yet recruitingPhase NA

Efficacy and Safety of Tirzepatide (Spartina) in Chronic Kidney Failure

Safety and Effectiveness of Tirzepatide(Spartina )in Chronic Kidney Failure a Single-center Study

Asset

Tirzepatide

Subcutaneous · GLP-1 / GIP dual

Listed sites

1

Recruiting sites

—

Enrollment

15

estimated

Study population

Chronic kidney disease, Diabetes (other / unspecified), Obesity / overweight

Key I/E criterion

•BMI ≥27

Primary endpoint

•Body weight, absolute change (kg)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07176663
Org study IDSBMU-1404-06

Timeline

Milestones

Study first posted2025-09-16actual
Last update posted2025-12-15actual
Study start2026-02-01estimated
Primary completion2026-04-01estimated
Study completion2026-05-01estimated

Assets

Investigational agents

Tirzepatide

Study populations

Who this study enrolls

Chronic kidney diseaseDiabetes (other / unspecified)Obesity / overweight

Eligibility

Who can enroll

Minimum age18 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

age ≥18 years and history of diabetes or BMI over 27

Exclusion criteria

Previous usage of similar therapy for less than 3 months owing to the inability to capture all efficacy and safety endpoints within this brief timeframe and/or nonadherence to tirzepatide therapy

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Weight & body composition

1 endpoint
Primary/protocol endpoint

weight loss

Time frame:kilogram of weight loss measured by same scale one and three month after injection

Body weight, absolute change (kg)

change from baseline, improvement

Publications (10)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.